Order Article Reprints

Bauman JE, Julian R, Saba NF, Wise-Draper TM, Adkins DR, O’Brien P, Fidler MJ, Gibson MK, Duvvuri U, Heath-Chiozzi M, et al. Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer. Cancers. 2022; 14(10):2355. https://doi.org/10.3390/cancers14102355

Bauman, Julie E., Ricklie Julian, Nabil F. Saba, Trisha M. Wise-Draper, Douglas R. Adkins, Paul O’Brien, Mary Jo Fidler, Michael K. Gibson, Umamaheswar Duvvuri, Margo Heath-Chiozzi, and et al. 2022. "Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer" Cancers 14, no. 10: 2355. https://doi.org/10.3390/cancers14102355

Bauman, J. E., Julian, R., Saba, N. F., Wise-Draper, T. M., Adkins, D. R., O’Brien, P., Fidler, M. J., Gibson, M. K., Duvvuri, U., Heath-Chiozzi, M., Alvarado, D., Gedrich, R., Golden, P., & Cohen, R. B. (2022). Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer. Cancers, 14(10), 2355. https://doi.org/10.3390/cancers14102355